FDA Approves Novo Nordisk's Awiqli as First Weekly Insulin for Type 2 Diabetes

The FDA has approved Novo Nordisk's Awiqli (insulin icodec), the first once-weekly insulin for adults with type 2 diabetes, according to Endpoints News. The Thursday approval marks a significant shift from daily injections that have defined diabetes care for decades, giving patients an alternative to daily basal insulin treatments.

Awiqli reduces the treatment burden from 365 injections per year to just 52, potentially improving adherence in a population where injection fatigue often undermines glucose control. The drug uses a modified insulin molecule that releases slowly over seven days, maintaining steady background insulin levels that complement mealtime rapid-acting insulin.

For patients currently struggling with daily insulin adherence, Awiqli offers immediate practical benefits. Missing a daily insulin dose can lead to dangerous blood sugar spikes, while a weekly schedule may prove easier to maintain for those who frequently miss doses or find daily injections burdensome. The weekly option may prove especially valuable for patients with complex medication regimens or those whose work schedules make consistent daily timing difficult.

The approval comes as GLP-1 medications have transformed diabetes and obesity treatment, but insulin remains essential for many patients whose beta cells can no longer produce adequate amounts of the hormone. Unlike GLP-1 drugs that enhance the body's own insulin production, Awiqli directly replaces the insulin that patients with advanced type 2 diabetes can no longer make sufficiently.

Insurance coverage will likely prove crucial for adoption, as patients often face significant out-of-pocket costs for newer insulin formulations. The cost and coverage landscape for new insulin products has historically varied widely, with some patients paying hundreds of dollars monthly depending on their insurance plans.

What This Means for Patients

Patients considering Awiqli should discuss the weekly option with their healthcare providers, particularly those currently taking daily basal insulin. However, patients should not expect Awiqli to replace the need for careful blood glucose monitoring or mealtime insulin management. The drug addresses only basal insulin needs, and most patients will still require rapid-acting insulin with meals. Those considering a switch from daily basal insulin should work closely with their diabetes care team to ensure proper dosing conversion and monitoring during the transition period.